二甲双胍通过抑制p38 MAPK磷酸化减少睾酮诱导的卵巢颗粒细胞内质网应激
研究探讨二甲双胍能否抑制雄激素诱导的卵巢颗粒细胞内质网应激。收集25例PCOS与25例对照的卵丘细胞和卵泡液,构建DHT诱导PCOS小鼠模型并予二甲双胍,结合原代颗粒细胞与卵丘-卵母细胞复合体体外实验。结果显示二甲双胍通过抑制p38 MAPK磷酸化减轻睾酮诱导的内质网应激及UPR激活。
要点
- PCOS患者卵丘细胞内质网应激标志物GRP78、CHOP、XBP1s及UPR感受器蛋白高于对照
- DHT诱导PCOS小鼠卵巢、颗粒细胞和COCs的内质网应激标志物升高并伴p38 MAPK磷酸化
- 二甲双胍或p38 MAPK抑制可减轻睾酮诱导的内质网应激及LH给药下的COC快速扩展
核心结论
- 二甲双胍通过抑制卵巢颗粒细胞中p38 MAPK磷酸化,抑制睾酮诱导的内质网应激和UPR激活。
研究设计与样本
- 收集25例PCOS与25例对照的卵丘细胞和卵泡液,检测UPR感受器蛋白及UPR相关基因。
- 构建DHT诱导PCOS小鼠模型并给予或不给予二甲双胍,检测卵巢、卵母细胞、颗粒细胞和COCs。
- 原代小鼠颗粒细胞与COCs体外培养,分别加入睾酮、二甲双胍、p38 MAPK抑制剂或p38 MAPK siRNA。
主要发现
- PCOS患者卵丘细胞GRP78、CHOP、XBP1s表达及p-IRE1α、p-EIF2α、GRP78蛋白水平高于对照。
- DHT处理PCOS小鼠卵巢、颗粒细胞和COCs的内质网应激标志基因和蛋白水平升高,COCs和颗粒细胞中p38 MAPK磷酸化增加。
- 二甲双胍抑制内质网应激激活并伴随p-p38 MAPK水平降低。
- 体外实验中二甲双胍或p38 MAPK抑制减轻睾酮诱导的内质网应激。
- LH给药时睾酮促进COCs快速扩展及Areg、Ereg、Ptgs2、Sult1e1、Ptx3、Tnfaip6表达,二甲双胍、内质网应激抑制剂或p38 MAPK敲低可逆转。
临床怎么用
- 该研究为二甲双胍用于PCOS治疗提供进一步证据,提示其作用与抑制颗粒细胞p38 MAPK/内质网应激通路相关。
局限性
- 本研究中PCOS患者数量较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does metformin inhibit excessive androgen-induced endoplasmic reticulum (ER) stress in mouse granulosa cells (GCs) in vivo and in vitro? SUMMARY ANSWER: Metformin inhibits testosterone-induced ER stress and unfolded protein response (UPR) activation by suppressing p38 MAPK phosphorylation in ovarian GCs. WHAT IS KNOWN ALREADY: Polycystic ovary syndrome (PCOS) is associated with hyperandrogenism. Excessive testosterone induces ER stress and UPR activation in human cumulus cells, leading to cell apoptosis. Metformin has potential inhibitory effects on ER stress and UPR activation, as demonstrated in human pancreatic beta cells and obese mice. STUDY DESIGN, SIZE, DURATION: Cumulus cells and follicular fluid were collected from 25 women with PCOS and 25 controls at our IVF centre. A dihydrotestosterone (DHT)-induced PCOS mouse model was constructed and treated with or without metformin. Primary mouse GCs and cumulus-oocyte complexes (COCs) were cultured with testosterone, metformin, a p38 MAPK inhibitor, or p38 MAPK small interfering RNA. PARTICIPANTS/MATERIALS, SETTING, METHODS: The levels of UPR sensor proteins and UPR-related genes were measured in cumulus cells from PCOS and control patients by real-time quantitative PCR (qPCR) and western blot. The ovaries, oocytes, GCs and COCs were collected from PCOS mice treated with metformin and controls. The expressions of ER stress markers and p38 MAPK phosphorylation were assessed by qPCR, western blot and immunofluorescence. A subsequent in vitro analysis with primary cultured GCs and COCs was used to confirm the influence of metformin on ER stress activation by qPCR and western blot. Finally, the effects of ER stress activation on GCs and COCs in relation to LH responsiveness were examined by qPCR and COC expansion. MAIN RESULTS AND THE ROLE OF CHANCE: The expression of the ER stress markers GRP78, CHOP and XBP1s in the cumulus cells was higher in PCOS patients than in control patients, as were the levels of the UPR sensor proteins p-IRE1α, p-EIF2α and GRP78. Compared to those of control mice, the ovaries, GCs and COCs of DHT-treated PCOS mice showed increased levels of ER stress marker genes and proteins. Hyperandrogenism in PCOS mouse ovaries also induced p38 MAPK phosphorylation in COCs and GCs. Metformin inhibited ER stress activation was associated with decreased p-p38 MAPK levels. In vitro experiments, testosterone-induced ER stress was mitigated by metformin or p38 MAPK inhibition in primary cultured GCs and COCs. COCs expanded rapidly in the presence of testosterone during LH administration, and ovulation-related genes, namely, Areg, Ereg, Ptgs2, Sult1e1, Ptx3 and Tnfaip6, were strongly expressed in the COCs and GCs. These effects were reversed by treatment with metformin, an ER stress inhibitor or by knockdown of p38 MAPK. LIMITATIONS, REASONS FOR CAUTION: The number of PCOS patients in this study was small. WIDER IMPLICATIONS OF THE FINDINGS: This study provides further evidence for metformin as a PCOS treatment. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the National Key Research and Developmental Program of China (2018YFC1004800), the Key Research and Development Program of Zhejiang Province (2017C03022), the Zhejiang Province Medical Science and Technology Plan Project (2017KY085, 2018KY457), the National Natural Science Foundation of China (31701260, 81401264, 81701514), and the Special Funds for Clinical Medical Research of the Chinese Medical Association (16020320648). The authors report no conflict of interest in this work and have nothing to disclose. TRIAL REGISTRATION NUMBER: N/A.
引用
- Jin J, Ma Y, Tong X, et al. Metformin inhibits testosterone-induced endoplasmic reticulum stress in ovarian granulosa cells via inactivation of p38 MAPK. Hum Reprod. 2020. PMID: 32372097. doi:10.1093/humrep/deaa077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。